Nwankwo Christy, Livinski Alicia A, Heath Candrice R, Castelo-Soccio Leslie
University of Missouri- Kansas City School of Medicine, Kansas City, Missouri.
National Institutes of Health Library, Office of Research Services, National Institutes of Health, Bethesda, Maryland.
Int J Womens Dermatol. 2024 Aug 19;10(3):e173. doi: 10.1097/JW9.0000000000000173. eCollection 2024 Oct.
Despite the acknowledgment of the importance of social determinants of health (SDOH) on clinical outcomes, few clinical trials provide information about SDOH. Including these markers in pediatric dermatologic clinical trials may lead to improved care and novel observations about the disease.
Using a systematic review, assess the use of SDOH in pediatric dermatology clinical trials.
CINAHL Plus, Cochrane: CENTRAL, Embase, PubMed, and Scopus were searched. English language randomized controlled trials about pediatric dermatology diseases published from January 2011 to May 2022 were included. Two authors independently screened all records using Covidence at 2 levels. Two authors independently collected data using Covidence and Microsoft Excel and assessed study quality. A protocol was registered at Open Science Framework: https://doi.org/10.17605/OSF.IO/B93VY.
A total of 6463 records were retrieved and 4298 were screened at title/abstract. Next, 1738 records were screened at full text and 1085 were included. Of these, 119 reported an SDOH factor for a pediatric dermatology disease. Income or socioeconomic status was the factor most reported followed by social support, location, and health insurance. Most of the studies were conducted outside of the United States.
There are a limited number of dermatology clinical trials that include a pediatric population.
Despite including over 1000 pediatric dermatology clinical trials, only 119 used SDOH. Pediatric dermatology researchers must prioritize including and reporting additional SDOH in clinical trials if the goal is to impact and improve clinical care and innovate for diverse populations of patients.
尽管人们认识到健康的社会决定因素（SDOH）对临床结果的重要性，但很少有临床试验提供有关SDOH的信息。在儿科皮肤病临床试验中纳入这些指标可能会改善护理并带来有关该疾病的新发现。
通过系统评价，评估SDOH在儿科皮肤病临床试验中的应用情况。
检索了CINAHL Plus、Cochrane：CENTRAL、Embase、PubMed和Scopus数据库。纳入2011年1月至2022年5月发表的关于儿科皮肤病疾病的英文随机对照试验。两位作者使用Covidence在两个层面独立筛选所有记录。两位作者使用Covidence和Microsoft Excel独立收集数据并评估研究质量。该方案已在开放科学框架注册：https://doi.org/10.17605/OSF.IO/B93VY。
共检索到6463条记录，在标题/摘要层面筛选了4298条。接下来，在全文层面筛选了1738条记录，纳入1085条。其中，119条报告了儿科皮肤病疾病的SDOH因素。收入或社会经济地位是报告最多的因素，其次是社会支持、地理位置和医疗保险。大多数研究在美国以外进行。
纳入儿科人群的皮肤病临床试验数量有限。
尽管纳入了1000多项儿科皮肤病临床试验，但只有119项使用了SDOH。如果目标是影响和改善临床护理并为不同患者群体进行创新，儿科皮肤病研究人员必须优先在临床试验中纳入并报告更多的SDOH。
